GTSM:6589

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

EirGenix Inc. operates as a contract development and manufacturing company worldwide. More Details


Snowflake Analysis

Mediocre balance sheet with limited growth.

Share Price & News

How has EirGenix's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 6589 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 6589's weekly volatility (6%) has been stable over the past year.


Market Performance


7 Day Return

-0.4%

6589

13.2%

TW Life Sciences

2.5%

TW Market


1 Year Return

55.0%

6589

123.3%

TW Life Sciences

31.6%

TW Market

Return vs Industry: 6589 underperformed the TW Life Sciences industry which returned 123.3% over the past year.

Return vs Market: 6589 exceeded the TW Market which returned 31.6% over the past year.


Shareholder returns

6589IndustryMarket
7 Day-0.4%13.2%2.5%
30 Day-17.5%19.8%11.8%
90 Day-31.9%42.7%22.9%
1 Year55.0%55.0%123.8%123.3%36.3%31.6%
3 Year59.9%58.7%163.0%161.3%59.7%41.8%
5 Yearn/a214.2%205.7%136.2%94.8%

Long-Term Price Volatility Vs. Market

How volatile is EirGenix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is EirGenix undervalued compared to its fair value and its price relative to the market?

3.69x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 6589's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 6589's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 6589 is unprofitable, so we can't compare its PE Ratio to the XA Life Sciences industry average.

PE vs Market: 6589 is unprofitable, so we can't compare its PE Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6589's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 6589 is good value based on its PB Ratio (3.7x) compared to the XA Life Sciences industry average (4.5x).


Next Steps

Future Growth

How is EirGenix forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

76.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 6589 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 6589 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 6589 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 6589's revenue (45.2% per year) is forecast to grow faster than the TW market (11.3% per year).

High Growth Revenue: 6589's revenue (45.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 6589 is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has EirGenix performed over the past 5 years?

-53.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 6589 is currently unprofitable.

Growing Profit Margin: 6589 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 6589 is unprofitable, and losses have increased over the past 5 years at a rate of 53.6% per year.

Accelerating Growth: Unable to compare 6589's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6589 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (25.8%).


Return on Equity

High ROE: 6589 has a negative Return on Equity (-47.19%), as it is currently unprofitable.


Next Steps

Financial Health

How is EirGenix's financial position?


Financial Position Analysis

Short Term Liabilities: 6589's short term assets (NT$1.8B) exceed its short term liabilities (NT$693.5M).

Long Term Liabilities: 6589's short term assets (NT$1.8B) exceed its long term liabilities (NT$1.3B).


Debt to Equity History and Analysis

Debt Level: 6589's debt to equity ratio (46.2%) is considered high.

Reducing Debt: Insufficient data to determine if 6589's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6589 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 6589 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 35.3% each year


Next Steps

Dividend

What is EirGenix current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6589's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6589's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6589's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6589's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 6589's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Cheng Lee

no data

Tenure

Dr. Cheng Liu Lee serves as Chief Executive Officer and President of EirGenix Inc. Dr. Lee has 30 years of product, process development and manufacturing experience in biotech, pharmaceutical and specialty...


Leadership Team

NamePositionTenureCompensationOwnership
Cheng Lee
CEO & Presidentno datano datano data
Hsiu Chuan Yang
VP & CFO2yrsno datano data
Chih-Jung Chang
VP & COO2yrsno datano data
Ping Yang Yeh
VP & CTO2yrsno datano data
Shang-Chung Ju
Executive Director & Chief Manufacturing Officer1yrno datano data
Thomas Schulze
Managing Director of EirGenix Europe GmbHno datano datano data
Ae-Ning Lin
Executive Director of Analytical Science and Quality Controlno datano datano data

2.0yrs

Average Tenure

Experienced Management: 6589's management team is considered experienced (2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21.9%.


Top Shareholders

Company Information

EirGenix Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: EirGenix Inc.
  • Ticker: 6589
  • Exchange: GTSM
  • Founded: 2012
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: NT$8.059b
  • Shares outstanding: 206.38m
  • Website: https://www.eirgenix.com

Number of Employees


Location

  • EirGenix Inc.
  • No. 101, Kangning Street
  • Lane 169
  • New Taipei City
  • 22180
  • Taiwan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
6589GTSM (Taipei Exchange)YesCommon SharesTWTWDNov 2016

Biography

EirGenix Inc. operates as a contract development and manufacturing company worldwide. Its services include cell line development and cell bank manufacturing, process development, analytical sciences and qu...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/23 08:42
End of Day Share Price2021/01/22 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.